UniQure Expects To Resolve FDA Clinical Hold Within Three Months

 
• By Joseph Haas
  
Hemophilia_525478450_1200.jpg
UniQure's gene therapy for hemophilia B faces a stumbling block

More from Gene Therapies

More from Advanced Therapies